Electromed, Inc. Form 10-Q Summary
Business context and reporting period
Electromed develops, manufactures, and markets SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation therapy. Products are sold through home care, institutional, distributor, and international channels. The filing covers the quarter and nine months ended March 31, 2022, Electromed’s fiscal 2022 third quarter; the request metadata refers to “2021 Q3,” but the filing period is March 31, 2022.
Key financial metrics
| Metric | Three months ended March 31, 2022 | Prior-year period | Nine months ended March 31, 2022 | Prior-year period |
|---|---|---|---|---|
| Net revenue | $10.141 million | $8.787 million | $30.390 million | $26.287 million |
| Gross profit | $7.743 million | $6.701 million | $23.324 million | $20.374 million |
| Gross margin | 76.4% | 76.3% | 76.7% | 77.5% |
| Operating income | $863,000 | $243,000 | $2.477 million | $2.488 million |
| Net income | $645,000 | $224,000 | $1.922 million | $1.962 million |
| Diluted EPS | $0.07 | $0.03 | $0.22 | $0.22 |
- Quarterly revenue increased 15.4%; nine-month revenue increased 15.6%.
- Home care revenue rose 10.7% for the quarter and 13.0% for the nine-month period, driven by higher referrals, approvals, clinic access, the CMS waiver, and a January 2022 Medicare allowable-rate increase.
- Quarterly home care distributor revenue increased 395.2%, while nine-month distributor revenue increased 146.1%, primarily due to demand from a major distribution partner.
- Quarterly operating income more than tripled year over year, but nine-month operating income was essentially unchanged because of higher SG&A and other strategic investments.
- As of March 31, 2022, cash and cash equivalents were $9.844 million versus $11.889 million at June 30, 2021. Working capital was $28.022 million.
- Net cash provided by operating activities was only $53,000 for the nine months, compared with $2.324 million in the prior-year period. Accounts receivable increased $2.582 million, principally because Medicare receivables generally have a 13-month payment cycle.
- Investing cash use was $1.066 million, including $980,000 for property and equipment and $86,000 for finite-life intangible assets.
- Financing cash use was $1.032 million, including $962,000 of share repurchases and $70,000 of taxes paid on net share settlements.
- The company had no outstanding borrowings and had the full $2.5 million revolving credit facility available at March 31, 2022. The facility expires December 18, 2023, subject to renewal.
- Total liabilities were $5.009 million and shareholders’ equity was $34.010 million at March 31, 2022.
Material changes versus the prior comparable periods
- Revenue growth was broad-based, led by home care, distributor, and international sales. Institutional revenue declined 11.5% in the quarter because of lower capital purchases, although consumable wrap volume increased 16.5%.
- Gross margin was stable in the quarter but declined 80 basis points for the nine-month period because of higher raw-material and shipping costs, partly offset by pricing, efficiency, and operating leverage.
- SG&A increased 8.1% in the quarter and 20.1% for the nine-month period. Drivers included personnel additions, higher compensation, travel, recruiting, insurance, systems infrastructure, clinical studies, and higher incentive payments.
- Research and development expense decreased 17.4% in the quarter and 25.4% for the nine-month period, primarily because of lower professional-service costs related to next-generation platform development.
- Cash declined $2.045 million during the nine months, reflecting weak operating cash generation, capital expenditures, and share repurchases.
- The company repurchased 24,551 shares during the quarter for approximately $299,000, at an average price of $12.21 per share. Approximately $913,000 remained available under the repurchase authorization at March 31, 2022.
Guidance, outlook, risks, and unusual items
- Management believes working capital, operating performance, and available borrowings will provide adequate liquidity through fiscal 2022; no formal revenue or earnings guidance is provided.
- COVID-19 continued to restrict clinic access and affect hospital protocols, although access and patient flow improved in March 2022 and the company reported record monthly referrals. The company expects pandemic effects to continue.
- The CMS respiratory-device waiver was extended for an additional 90-day period beginning April 16, 2022. Management identified potential risk from expiration of the waiver, currently expected in July 2022, although improved face-to-face access and sales execution may mitigate the effect.
- Supply-chain timelines lengthened and raw-material and shipping costs increased. Management expects further increases, particularly for electronic components, which could reduce gross margins. No material product-availability disruption had occurred through the filing date.
- Management is investing in ERP, customer relationship management, revenue-cycle systems, tooling, sales-force expansion, and clinical studies.
- The IRS is examining fiscal 2020. No formal assessment had been issued, and the ultimate effect, if any, is not determinable.
- A putative class-action lawsuit related to a previously announced data breach was filed in September 2021. The company moved to dismiss the complaint and stated that it could not determine the ultimate outcome or potential loss exposure.
- Key risks include changes to Medicare, Medicaid, and private-payer reimbursement; COVID-19 developments; supply-chain disruptions; regulatory compliance; competition; cyberattacks and data breaches; international sales; sales-force expansion; and access to or renewal of the credit facility.
- Critical estimates include variable consideration in home-care revenue, inventory valuation, share-based compensation, and warranty reserves. The warranty reserve was $938,000 at March 31, 2022.
Important facts for investors to verify
- Whether the CMS waiver expires, is extended, or changes reimbursement and referral approval rates after July 2022.
- Collection timing and credit quality of the growing Medicare-related accounts receivable balance.
- Whether raw-material, electronic-component, freight, and other supply-chain costs continue to pressure gross margins.
- Progress and future cost of the ERP, revenue-cycle, CRM, tooling, and clinical-study investments.
- The outcome and potential financial exposure from the data-breach litigation and the ongoing IRS examination.
- Compliance with the revolving credit facility’s covenants and availability of the $2.5 million borrowing capacity through its December 2023 expiration.
- The sustainability of distributor-driven growth and the effect of quarterly timing fluctuations in institutional and international purchases.